000829377 001__ 829377
000829377 005__ 20240625095128.0
000829377 0247_ $$2doi$$a10.1021/jacs.6b12950
000829377 0247_ $$2ISSN$$a0002-7863
000829377 0247_ $$2ISSN$$a1520-5126
000829377 0247_ $$2WOS$$aWOS:000398764000030
000829377 0247_ $$2altmetric$$aaltmetric:17344335
000829377 0247_ $$2pmid$$apmid:28290199
000829377 037__ $$aFZJ-2017-03090
000829377 041__ $$aEnglish
000829377 082__ $$a540
000829377 1001_ $$00000-0002-7102-1840$$aCasasnovas, Rodrigo$$b0
000829377 245__ $$aUnbinding Kinetics of a p38 MAP Kinase Type II Inhibitor from Metadynamics Simulations
000829377 260__ $$aWashington, DC$$bAmerican Chemical Society$$c2017
000829377 3367_ $$2DRIVER$$aarticle
000829377 3367_ $$2DataCite$$aOutput Types/Journal article
000829377 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1492523066_26748
000829377 3367_ $$2BibTeX$$aARTICLE
000829377 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000829377 3367_ $$00$$2EndNote$$aJournal Article
000829377 520__ $$aUnderstanding the structural and energetic requisites of ligand binding toward its molecular target is of paramount relevance in drug design. In recent years, atomistic free energy calculations have proven to be a valid tool to complement experiments in characterizing the thermodynamic and kinetic properties of protein/ligand interaction. Here, we investigate, through a recently developed metadynamics-based protocol, the unbinding mechanism of an inhibitor of the pharmacologically relevant target p38 MAP kinase. We provide a thorough description of the ligand unbinding pathway identifying the most stable binding mode and other thermodynamically relevant poses. From our simulations, we estimated the unbinding rate as koff = 0.020 ± 0.011 s–1. This is in good agreement with the experimental value (koff = 0.14 s–1). Next, we developed a Markov state model that allowed identifying the rate-limiting step of the ligand unbinding process. Our calculations further show that the solvation of the ligand and that of the active site play crucial roles in the unbinding process. This study paves the way to investigations on the unbinding dynamics of more complex p38 inhibitors and other pharmacologically relevant inhibitors in general, demonstrating that metadynamics can be a powerful tool in designing new drugs with engineered binding/unbinding kinetics.
000829377 536__ $$0G:(DE-HGF)POF3-574$$a574 - Theory, modelling and simulation (POF3-574)$$cPOF3-574$$fPOF III$$x0
000829377 588__ $$aDataset connected to CrossRef
000829377 7001_ $$0P:(DE-HGF)0$$aLimongelli, Vittorio$$b1
000829377 7001_ $$0P:(DE-HGF)0$$aTiwary, Pratyush$$b2
000829377 7001_ $$0P:(DE-Juel1)145614$$aCarloni, Paolo$$b3$$eCorresponding author
000829377 7001_ $$0P:(DE-HGF)0$$aParrinello, Michele$$b4$$eCorresponding author
000829377 773__ $$0PERI:(DE-600)1472210-0$$a10.1021/jacs.6b12950$$gVol. 139, no. 13, p. 4780 - 4788$$n13$$p4780 - 4788$$tJournal of the American Chemical Society$$v139$$x1520-5126$$y2017
000829377 8564_ $$uhttps://juser.fz-juelich.de/record/829377/files/jacs%252E6b12950.pdf$$yRestricted
000829377 8564_ $$uhttps://juser.fz-juelich.de/record/829377/files/jacs%252E6b12950.gif?subformat=icon$$xicon$$yRestricted
000829377 8564_ $$uhttps://juser.fz-juelich.de/record/829377/files/jacs%252E6b12950.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000829377 8564_ $$uhttps://juser.fz-juelich.de/record/829377/files/jacs%252E6b12950.jpg?subformat=icon-180$$xicon-180$$yRestricted
000829377 8564_ $$uhttps://juser.fz-juelich.de/record/829377/files/jacs%252E6b12950.jpg?subformat=icon-640$$xicon-640$$yRestricted
000829377 8564_ $$uhttps://juser.fz-juelich.de/record/829377/files/jacs%252E6b12950.pdf?subformat=pdfa$$xpdfa$$yRestricted
000829377 8767_ $$8APC502490952$$92017-10-25$$d2017-10-26$$eHybrid-OA$$jZahlung erfolgt$$zUSD 2000,-
000829377 909CO $$ooai:juser.fz-juelich.de:829377$$popenCost$$pOpenAPC$$pVDB
000829377 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145614$$aForschungszentrum Jülich$$b3$$kFZJ
000829377 9131_ $$0G:(DE-HGF)POF3-574$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vTheory, modelling and simulation$$x0
000829377 9141_ $$y2017
000829377 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000829377 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000829377 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000829377 915__ $$0StatID:(DE-HGF)0550$$2StatID$$aNo Authors Fulltext
000829377 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ AM CHEM SOC : 2015
000829377 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ AM CHEM SOC : 2015
000829377 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000829377 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000829377 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000829377 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000829377 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000829377 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000829377 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000829377 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000829377 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000829377 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000829377 920__ $$lyes
000829377 9201_ $$0I:(DE-Juel1)IAS-5-20120330$$kIAS-5$$lComputational Biomedicine$$x0
000829377 9201_ $$0I:(DE-Juel1)INM-9-20140121$$kINM-9$$lComputational Biomedicine$$x1
000829377 980__ $$ajournal
000829377 980__ $$aVDB
000829377 980__ $$aUNRESTRICTED
000829377 980__ $$aI:(DE-Juel1)IAS-5-20120330
000829377 980__ $$aI:(DE-Juel1)INM-9-20140121
000829377 980__ $$aAPC